Complete CDMO Services Position as an end-to-end CDMO for cosmetics and nutraceuticals that need bench-to-production support. BDI biotech provides strain selection and improvement, bioprocess development and scale-up up to 500 L non-GMP and 2000 L GMP ISO 13485, enabling a smooth transition from lab to commercial batches. This makes them a strong partner for startups and mid-sized brands aiming to reduce development risk and speed time-to-market.

LBP Expertise Leverage their Live Biotherapeutic Product LBP capability to attract probiotic and live biotherapeutic developers. Their strength in strain optimization downstream processing and GMP-scale production positions BDI biotech as a mid-scale manufacturing partner for probiotic projects and nutraceuticals with live microbial ingredients.

European Nearshore Capacity Capitalize on an EU-based manufacturing footprint. Located in Spain, BDI biotech serves European clients with regulatory-compliant processes including GMP and ISO 13485, offering potential for shorter lead times and closer collaboration compared with offshore partners.

End to End Highlight integrated downstream capabilities. With equipment for centrifugation, high pressure homogenization, filtration and chromatography on all lines, BDI biotech provides end-to-end process development and production under one roof, reducing vendor management complexity for clients.

Startup Collaboration Target early-stage and funded firms through industry networks. Their participation in EFIB, BIOSPAIN and LIFE platform meetings signals active industry engagement and readiness for partnerships, making them a good fit for co-development contracts, sponsored R&D, and accelerator collaborations.